(UroToday.com) The PD-1 inhibitor pembrolizumab has shown activity in a study of heavily pretreated patients with PD-L1-positive advanced prostate cancer and in a study of PD-L1-positive or PD-L1-negative patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel who received more than one next-generation hormonal agent.1 Pembrolizumab plus docetaxel and prednisone (cohort B) has shown antitumor activity in patients with mCRPC in the phase I/II KEYNOTE-365 study (NCT02861573). At the virtual ESMO 2020 meeting, Dr. Emanuela Romano and colleagues presented updated results after increased enrollment, extended follow-up, and new radiologic findings by a blinded independent review.